BFLY vs. ALIM, CAPR, ME, GLSI, GOSS, DRTS, MASS, PROF, TRVI, and VERU
Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include Alimera Sciences (ALIM), Capricor Therapeutics (CAPR), 23andMe (ME), Greenwich LifeSciences (GLSI), Gossamer Bio (GOSS), Alpha Tau Medical (DRTS), 908 Devices (MASS), Profound Medical (PROF), Trevi Therapeutics (TRVI), and Veru (VERU). These companies are all part of the "medical" sector.
Alimera Sciences (NASDAQ:ALIM) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.
Alimera Sciences has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Alimera Sciences presently has a consensus price target of $7.50, indicating a potential upside of 116.76%. Given Butterfly Network's higher possible upside, equities research analysts clearly believe Alimera Sciences is more favorable than Butterfly Network.
99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 37.9% of Butterfly Network shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by company insiders. Comparatively, 27.2% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Alimera Sciences and Alimera Sciences both had 2 articles in the media. Alimera Sciences' average media sentiment score of 0.74 beat Butterfly Network's score of 0.00 indicating that Butterfly Network is being referred to more favorably in the news media.
Alimera Sciences has a net margin of -24.93% compared to Alimera Sciences' net margin of -202.88%. Alimera Sciences' return on equity of -50.87% beat Butterfly Network's return on equity.
Alimera Sciences received 350 more outperform votes than Butterfly Network when rated by MarketBeat users. However, 62.50% of users gave Butterfly Network an outperform vote while only 57.72% of users gave Alimera Sciences an outperform vote.
Alimera Sciences has higher revenue and earnings than Butterfly Network. Alimera Sciences is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.
Summary
Alimera Sciences beats Butterfly Network on 10 of the 16 factors compared between the two stocks.
Get Butterfly Network News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Butterfly Network Competitors List
Related Companies and Tools
